Trial Profile
A Phase III, Multi-center Study to Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-linking in Eyes With Progressive Keratoconus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Riboflavin (Primary)
- Indications Keratoconus
- Focus Registrational; Therapeutic Use
- Sponsors Avedro; Glaukos Corporation
- 25 Feb 2021 According to a Glaukos Corporation media release, this Phase 3 trial results are expected to support the U.S. NDA submission in 2022 and the company is targeting U.S. FDA approval for Epi-on in 2023.
- 25 Feb 2021 Primary endpoint (Improvement in maximum corneal curvature (Kmax) at 6 months from baseline between the treated and placebo-controlled arms) has been met, according to a Glaukos Corporation media release.
- 25 Feb 2021 Results presented in a Glaukos Corporation media release.